{"drugs":["Histrelin Acetate","Supprelin LA","Vantas"],"mono":{"0":{"id":"284920-s-0","title":"Generic Names","mono":"Histrelin Acetate"},"1":{"id":"284920-s-1","title":"Dosing and Indications","sub":{"0":{"id":"284920-s-1-4","title":"Adult Dosing","mono":"<b>Carcinoma of prostate, Advanced (palliative treatment):<\/b> one 50-mg implant inserted SUBQ for 12 months "},"1":{"id":"284920-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not indicated for use in pediatric patients (Vantas(R))<\/li><li><b>Central precocious puberty:<\/b> one 50-mg implant inserted SUBQ every 12 months (Supprelin(R) LA)<\/li><\/ul>"},"3":{"id":"284920-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Carcinoma of prostate, Advanced (palliative treatment)<\/li><li>Central precocious puberty<\/li><\/ul>"}}},"3":{"id":"284920-s-3","title":"Contraindications\/Warnings","sub":[{"id":"284920-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to gonadotropin-releasing hormone (GnRH), GnRH agonist analogs, or any component of the product<\/li><li>pregnancy; may cause fetal harm and spontaneous abortion<\/li><\/ul>"},{"id":"284920-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- increased risk of myocardial infarction, sudden cardiac death, and stroke have been reported; monitoring recommended<\/li><li>-- androgen deprivation may prolong QT interval, evaluate benefit\/risk of use in patients with congenital long QT syndrome, congenital heart failure, frequent electrolyte abnormalities, and concomitant QT-prolonging drugs; monitoring recommended<\/li><li>Endocrine or Metabolic:<\/li><li>-- hyperglycemia and new onset or worsening of glycemic control in diabetes mellitus has been reported; monitoring recommended<\/li><li>-- transient increase in testosterone during the first week of therapy may result in exacerbation symptoms or onset of new symptoms (eg, bone pain, neuropathy, hematuria, ureteral\/bladder outlet obstruction)<\/li><li>Other:<\/li><li>-- anaphylaxis has been reported<\/li><li>-- spontaneous extrusion of implant has been reported; monitoring recommended<\/li><li>-- ureteral obstruction and spinal cord compression, has been reported; monitoring recommended in patients with metastatic vertebral lesions or urinary tract obstruction, particularly during first few weeks of treatment<\/li><\/ul>"},{"id":"284920-s-3-11","title":"Pregnancy Category","mono":"Histrelin: X (FDA)<br\/>"},{"id":"284920-s-3-12","title":"Breast Feeding","mono":"Histrelin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"284920-s-4","title":"Drug Interactions","sub":[{"id":"284920-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Mesoridazine (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"284920-s-4-14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Pipamperone (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"}]},"5":{"id":"284920-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Implant site reaction (5.8% to 51.1%)<\/li><li><b>Endocrine metabolic:<\/b>Gynecomastia (4.1%), Hot sweats (65.5%)<\/li><li><b>Reproductive:<\/b>Amenorrhea, Erectile dysfunction<\/li><li><b>Other:<\/b>Fatigue (9.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Pituitary apoplexy<\/li><li><b>Hepatic:<\/b>Injury of liver (Severe)<\/li><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Renal:<\/b>Renal impairment (Mild) (4.7%)<\/li><\/ul>"},"6":{"id":"284920-s-6","title":"Drug Name Info","sub":{"0":{"id":"284920-s-6-17","title":"US Trade Names","mono":"<ul><li>Vantas<\/li><li>Supprelin LA<\/li><\/ul>"},"2":{"id":"284920-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Gonadotropin Releasing Hormone Agonist<\/li><\/ul>"},"3":{"id":"284920-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"284920-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"284920-s-7","title":"Mechanism Of Action","mono":"Histrelin acetate is a luteinizing hormone-releasing hormone (LH-RH) agonist that inhibits gonadotropin secretion. It increases levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) upon initiation of treatment but decreases at continuous administration of the drug.<br\/>"},"8":{"id":"284920-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"284920-s-8-23","title":"Absorption","mono":"Bioavailability: 92% <br\/>"},"1":{"id":"284920-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 58.4 L +\/- 7.86 L<\/li><li>Protein binding: 29.5% +\/- 8.9% unbound<\/li><\/ul>"},"2":{"id":"284920-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; C-terminal dealkylation and hydrolysis<\/li><li>Metabolites: peptide fragments<\/li><\/ul>"},"4":{"id":"284920-s-8-27","title":"Elimination Half Life","mono":"3.92 h +\/- 1.01 h <br\/>"}}},"9":{"id":"284920-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>open implant vial just prior to insertion; do not bend or pinch the implant<\/li><li>remove the old implant at the time of administration of the new implant<\/li><li>under anesthesia, insert in the inner aspect of the upper arm halfway between the shoulder and the elbow and in the crease between the biceps and triceps<\/li><\/ul>"},"10":{"id":"284920-s-10","title":"Monitoring","mono":"<ul><li>advanced prostate cancer: serum testosterone and PSA levels, periodically; for evidence of therapeutic response<\/li><li>central precocious puberty: luteinizing hormone, follicle stimulating hormone, and estradiol or testosterone levels at 1 month after insertion and then every 6 months thereafter, and height and bone age, every 6 to 12 months; for evidence of therapeutic response<\/li><li>blood glucose and\/or HbA1c levels, periodically<\/li><li>electrolytes; periodically during treatment<\/li><li>spinal cord compression and ureteral obstruction; in at risk patients<\/li><li>signs and symptoms of cardiovascular disease<\/li><li>ECG; periodically during treatment<\/li><\/ul>"},"11":{"id":"284920-s-11","title":"How Supplied","mono":"<ul><li><b>Supprelin LA<\/b><br\/>Subcutaneous Implant: 50 MG<br\/><\/li><li><b>Vantas<\/b><br\/>Subcutaneous Implant: 50 MG<br\/><\/li><\/ul>"},"12":{"id":"284920-s-12","title":"Toxicology","sub":[{"id":"284920-s-12-31","title":"Clinical Effects","mono":"<b>HISTRELIN<\/b><br\/>OVERDOSE: No information available. ADVERSE EFFECTS: FREQUENT - hot flashes and fatigue, as well as, bruising and pain\/soreness\/tenderness at the site of insertion. INFREQUENT - erythema and swelling at the insertion site, weight gain, erectile dysfunction, gynecomastia, testicular atrophy, decreased libido, insomnia, constipation, headache and mild renal impairment.<br\/>"},{"id":"284920-s-12-32","title":"Treatment","mono":"<b>HISTRELIN<\/b><br\/>Support: Treatment is symptomatic and supportive. There is no antidote available.<br\/>"},{"id":"284920-s-12-33","title":"Range of Toxicity","mono":"<b>HISTRELIN<\/b><br\/>TOXICITY: A specific toxic dose has not been established. THERAPEUTIC DOSE: The recommended dose is one implant inserted subcutaneously in the inner aspect of the upper arm for 12 months.<br\/>"}]},"13":{"id":"284920-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid wetting the arm with the implant for 24 hours and refrain from heavy lifting or strenuous exertion of the arm with the implant for 7 days after implant insertion.<\/li><li>Instruct patient on proper handling of dressing and any follow up regarding stitches, if appropriate.<\/li><li>Vantas(TM) implant may cause gynecomastia, hot sweats, nausea, vomiting, headache, insomnia, amenorrhea, erectile dysfunction, or fatigue.<\/li><li>Supprelin(R) LA implant may cause pain, swelling, or redness in or around the incision site.<\/li><li>Instruct patients to report new or worsening bone pain, weakness or numbness in legs, hematuria, or dysuria.<\/li><li>Advise caregiver that the child may experience initial new-onset or worsening of puberty symptoms (eg; light vaginal bleeding and breast enlargement in girls) with Supprelin(R) LA therapy, but that symptoms should resolve within 4 weeks.<\/li><\/ul>"}}}